# A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma

Source: https://onco.cc/trials/nct04712643/  
OnCo record `nct04712643` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Atezolizumab, Bevacizumab in hepatocellular carcinoma, run by Hoffmann-La Roche, active and no longer recruiting.

## Summary

A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma is a phase 3 interventional study registered as NCT04712643 by Hoffmann-La Roche, with 342 participants enrolled, started 2021-03-12 and due to reach its primary completion in 2029-02-01. Interventions recorded: Atezolizumab, Becavizumab, Transarterial chemoembolization (TACE). Conditions listed: Hepatocellular Carcinoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT04712643
- Phase: 3
- Setting: A Phase III, Open-Label, Randomized Study of On-Demand TACE Combined With Atezolizumab Plus Bevacizumab (Atezo/Bev) or On-Demand TACE Alone in Patients With Untreated Heaptocellular Carcionma
- Sponsor: Hoffmann-La Roche
- Enrolled: 342

## Sources

- ClinicalTrials.gov NCT04712643: https://clinicaltrials.gov/study/NCT04712643

## Connected records

- cancers: [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/)
- drugs: [Atezolizumab](https://onco.cc/drugs/atezolizumab/), [Bevacizumab](https://onco.cc/drugs/bevacizumab/)
- companies: [Roche / Genentech](https://onco.cc/companies/roche-genentech/)

---
JSON: https://onco.cc/api/v1/entities/nct04712643.json